Immunosuppression for management of Crohn's disease - Author's reply

Affiliations

Comment

Reena Khanna et al. Lancet. 2016.

. 2016 Feb 20;387(10020):748.

doi: 10.1016/S0140-6736(16)00011-8. Epub 2016 Feb 18.

¹ Department of Medicine, Robarts Clinical Trials, University of Western Ontario, London, ON N6A 5K8, Canada. Electronic address: rkhanna3@uwo.ca.

No abstract available

Comment on

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG; REACT Study Investigators. Khanna R, et al. Lancet. 2015 Nov 7;386(10006):1825-34. doi: 10.1016/S0140-6736(15)00068-9. Epub 2015 Sep 3. Lancet. 2015. PMID: 26342731 Clinical Trial.
Immunosuppression for management of Crohn's disease.
Herfarth HH, Long MD, Kappelman MD. Herfarth HH, et al. Lancet. 2016 Feb 20;387(10020):747-8. doi: 10.1016/S0140-6736(16)00327-5. Epub 2016 Feb 18. Lancet. 2016. PMID: 26906660 No abstract available.
Immunosuppression for management of Crohn's disease.
Milosevic I, Dale A, Drysdale H, Mahtani K; COMPare project team. Milosevic I, et al. Lancet. 2016 Feb 20;387(10020):747. doi: 10.1016/S0140-6736(16)00326-3. Epub 2016 Feb 18. Lancet. 2016. PMID: 26906661 No abstract available.